Record Information |
---|
Version | 2.0 |
---|
Created at | 2005-11-16 15:48:42 UTC |
---|
Updated at | 2024-09-17 15:44:45 UTC |
---|
NP-MRD ID | NP0001285 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | SM(d18:1/18:0) |
---|
Description | Sphingomyelin (d18:1/18:0) Or SM(d18:1/18:0) Is a type of sphingolipid found in animal cell membranes, especially in the membranous myelin sheath which surrounds some nerve cell axons. It usually consists of phosphorylcholine and ceramide. SM(d18:1/18:0) Consists of a sphingosine backbone and a stearic acid chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase. |
---|
Structure | [H][C@@](COP([O-])(=O)OCC[N+](C)(C)C)(NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC InChI=1S/C41H83N2O6P/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-41(45)42-39(38-49-50(46,47)48-37-36-43(3,4)5)40(44)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2/h32,34,39-40,44H,6-31,33,35-38H2,1-5H3,(H-,42,45,46,47)/b34-32+/t39-,40+/m0/s1 |
---|
Synonyms | Value | Source |
---|
(2S,3R,4E)-3-Hydroxy-2-(stearoylamino)octadec-4-en-1-yl 2-(trimethylammonio)ethyl phosphate | ChEBI | 2,3-(N-Steroylsphingosyl)-1-phosphocholine | ChEBI | 2,3-SPPC | ChEBI | C18 Sphingomyelin | ChEBI | N-(Octadecanoyl)-sphing-4-enine-1-phosphocholine | ChEBI | N-Octadecanoylsphing-4-enine-1-phosphocholine | ChEBI | N-Octadecanoylsphingosine-1-phosphocholine | ChEBI | N-Stearoylsphing-4-enine-1-phosphocholine | ChEBI | Sphingomyelin (D18:1/18:0) | ChEBI | Stearoyl sphingomyelin | ChEBI | (2S,3R,4E)-3-Hydroxy-2-(stearoylamino)octadec-4-en-1-yl 2-(trimethylammonio)ethyl phosphoric acid | Generator | C18-Sphingomyelin | HMDB | N-Stearoyl-D-erythro-sphingosylphosphorylcholine | HMDB | N-Stearoylsphingomyelin | HMDB | N-Stearoylsphingosine-1-phosphocholine | HMDB | Sphingomyelin 18:0 | HMDB | Stearoylsphingomyelin | HMDB | Sphingomyelin | HMDB | N-(Octadecanoyl)-1-phosphocholine-sphing-4-enine | HMDB | Sphingomyelin(D18:1/18:0) | HMDB | N-(Octadecanoyl)-1-phosphocholine-sphingosine | HMDB | N-(Octadecanoyl)-1-phosphocholine-D-erythro-sphingosine | HMDB | N-(Octadecanoyl)-1-phosphocholine-4-sphingenine | HMDB | N-(Octadecanoyl)-1-phosphocholine-D-sphingosine | HMDB | N-(Octadecanoyl)-1-phosphocholine-sphingenine | HMDB | N-(Octadecanoyl)-1-phosphocholine-erythro-4-sphingenine | HMDB | SM(D18:1/18:0) | HMDB, ChEBI |
|
---|
Chemical Formula | C41H84N2O6P |
---|
Average Mass | 732.0892 Da |
---|
Monoisotopic Mass | 731.60670 Da |
---|
IUPAC Name | (2-{[(2S,3R,4E)-3-hydroxy-2-octadecanamidooctadec-4-en-1-yl phosphono]oxy}ethyl)trimethylazanium |
---|
Traditional Name | (2-{[(2S,3R,4E)-3-hydroxy-2-octadecanamidooctadec-4-en-1-yl phosphono]oxy}ethyl)trimethylazanium |
---|
CAS Registry Number | 85187-10-6 |
---|
SMILES | [H][C@@](O)(\C=C\CCCCCCCCCCCCC)[C@]([H])(COP(O)(=O)OCC[N+](C)(C)C)NC(=O)CCCCCCCCCCCCCCCCC |
---|
InChI Identifier | InChI=1S/C41H83N2O6P/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-41(45)42-39(38-49-50(46,47)48-37-36-43(3,4)5)40(44)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2/h32,34,39-40,44H,6-31,33,35-38H2,1-5H3,(H-,42,45,46,47)/p+1/b34-32+/t39-,40+/m0/s1 |
---|
InChI Key | LKQLRGMMMAHREN-YJFXYUILSA-O |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, CD3OD, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as phosphosphingolipids. These are sphingolipids with a structure based on a sphingoid base that is attached to a phosphate head group. They differ from phosphonospingolipids which have a phosphonate head group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Sphingolipids |
---|
Sub Class | Phosphosphingolipids |
---|
Direct Parent | Phosphosphingolipids |
---|
Alternative Parents | |
---|
Substituents | - Sphingoid-1-phosphate or derivatives
- Phosphocholine
- Phosphoethanolamine
- Dialkyl phosphate
- Fatty amide
- N-acyl-amine
- Organic phosphoric acid derivative
- Phosphoric acid ester
- Fatty acyl
- Alkyl phosphate
- Tetraalkylammonium salt
- Quaternary ammonium salt
- Secondary carboxylic acid amide
- Secondary alcohol
- Carboxamide group
- Carboxylic acid derivative
- Organic zwitterion
- Alcohol
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Carbonyl group
- Amine
- Organic salt
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, Turchan J, Nath A, Mattson MP: Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol. 2004 Feb;55(2):257-67. [PubMed:14755730 ]
- Harzer K, Massenkeil G, Frohlich E: Concurrent increase of cholesterol, sphingomyelin and glucosylceramide in the spleen from non-neurologic Niemann-Pick type C patients but also patients possibly affected with other lipid trafficking disorders. FEBS Lett. 2003 Feb 27;537(1-3):177-81. [PubMed:12606053 ]
- He X, Chen F, McGovern MM, Schuchman EH: A fluorescence-based, high-throughput sphingomyelin assay for the analysis of Niemann-Pick disease and other disorders of sphingomyelin metabolism. Anal Biochem. 2002 Jul 1;306(1):115-23. [PubMed:12069422 ]
- Reichl D, Sterchi JM: Human peripheral lymph lipoproteins are enriched in sphingomyelin. Biochim Biophys Acta. 1992 Jul 9;1127(1):28-32. [PubMed:1627631 ]
- Nelson JC, Jiang XC, Tabas I, Tall A, Shea S: Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2006 May 15;163(10):903-12. Epub 2006 Apr 12. [PubMed:16611667 ]
- Chen H, Born E, Mathur SN, Johlin FC Jr, Field FJ: Sphingomyelin content of intestinal cell membranes regulates cholesterol absorption. Evidence for pancreatic and intestinal cell sphingomyelinase activity. Biochem J. 1992 Sep 15;286 ( Pt 3):771-7. [PubMed:1417735 ]
- Liu KZ, Mantsch HH: Simultaneous quantitation from infrared spectra of glucose concentrations, lactate concentrations, and lecithin/sphingomyelin ratios in amniotic fluid. Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):696-702. [PubMed:10076150 ]
- Horter MJ, Sondermann S, Reinecke H, Bogdanski J, Woltering A, Kerber S, Breithardt G, Assmann G, Von Eckardstein A: Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta Physiol Scand. 2002 Oct;176(2):123-30. [PubMed:12354172 ]
- Tanaka K, Nishizawa K, Yamamoto H, Naruto T, Izeki E, Taga T, Shimada M, Saeki Y: Analysis of very long-chain fatty acids and plasmalogen in the erythrocyte membrane: a simple method for the detection of peroxisomal disorders and discrimination between adrenoleukodystrophy and Zellweger syndrome. Neuropediatrics. 1990 Aug;21(3):119-23. [PubMed:2234315 ]
- Cribier S, Morrot G, Neumann JM, Devaux PF: Lateral diffusion of erythrocyte phospholipids in model membranes comparison between inner and outer leaflet components. Eur Biophys J. 1990;18(1):33-41. [PubMed:2155112 ]
- Nyberg L, Duan RD, Axelson J, Nilsson A: Identification of an alkaline sphingomyelinase activity in human bile. Biochim Biophys Acta. 1996 Mar 29;1300(1):42-8. [PubMed:8608160 ]
- Whitworth NS, Magann EF, Morrison JC: Evaluation of fetal lung maturity in diamniotic twins. Am J Obstet Gynecol. 1999 Jun;180(6 Pt 1):1438-41. [PubMed:10368484 ]
- de Oliveira JS, Zaharenko AJ, de Freitas JC, Konno K, de Andrade SA, Portaro FC, Richardson M, Sant'anna OA, Tambourgi DV: Caissarolysin I (Bcs I), a new hemolytic toxin from the Brazilian sea anemone Bunodosoma caissarum: purification and biological characterization. Biochim Biophys Acta. 2006 Mar;1760(3):453-61. Epub 2006 Jan 17. [PubMed:16458433 ]
- Omarini LP, Frank-Burkhardt SE, Seemayer TA, Mentha G, Terrier F: Niemann-Pick disease type C: nodular splenomegaly. Abdom Imaging. 1995 Mar-Apr;20(2):157-60. [PubMed:7787722 ]
- Berna L, Asfaw B, Conzelmann E, Cerny B, Ledvinova J: Determination of urinary sulfatides and other lipids by combination of reversed-phase and thin-layer chromatographies. Anal Biochem. 1999 May 1;269(2):304-11. [PubMed:10222002 ]
- He X, Chen F, Gatt S, Schuchman EH: An enzymatic assay for quantifying sphingomyelin in tissues and plasma from humans and mice with Niemann-Pick disease. Anal Biochem. 2001 Jun 15;293(2):204-11. [PubMed:11399033 ]
- Feki NC, Therond P, Couturier M, Limea G, Legrand A, Jouannet P, Auger J: Human sperm lipid content is modified after migration into human cervical mucus. Mol Hum Reprod. 2004 Feb;10(2):137-42. [PubMed:14742699 ]
- Wang C, Yang J, Gao P, Lu X, Xu G: Identification of phospholipid structures in human blood by direct-injection quadrupole-linear ion-trap mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(17):2443-53. [PubMed:16059884 ]
- Otterbach B, Stoffel W: Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell. 1995 Jun 30;81(7):1053-61. [PubMed:7600574 ]
- Fujiwaki T, Yamaguchi S, Tasaka M, Sakura N, Taketomi T: Application of delayed extraction-matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in pericardial fluid, peritoneal fluid and serum from Gaucher disease patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Aug 25;776(1):115-23. [PubMed:12127332 ]
|
---|